Effectiveness of nanofiltration in removing small non‐enveloped viruses from three different plasma‐derived products
暂无分享,去创建一个
K. Zakrzewska | M. Bendinelli | A. Azzi | F. Corcioli | F. Maggi | V. Salotti | C. Farina | E. Andreoli | M. Menconi | P. Giovacchini
[1] J. Modrof,et al. Inactivation of parvovirus B19 during STIM‐4 vapor heat treatment of three coagulation factor concentrates , 2008, Transfusion.
[2] J. Blümel,et al. Kinetics of inactivating human parvovirus B19 and porcine parvovirus by dry‐heat treatment , 2008, Transfusion.
[3] C. Kempf,et al. Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses , 2007, Transfusion.
[4] A. Wieser,et al. Removal of small nonenveloped viruses by antibody‐enhanced nanofiltration during the manufacture of plasma derivatives , 2006, Transfusion.
[5] K. Zakrzewska,et al. Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification , 2006, Transfusion.
[6] J. Löwer,et al. Different susceptibility of B19 virus and mice minute virus to low pH treatment , 2004, Transfusion.
[7] N. Fujii,et al. Removal of small non‐enveloped viruses by nanofiltration , 2004, Vox sanguinis.
[8] A. Boner,et al. TT Virus in the Nasal Secretions of Children with Acute Respiratory Diseases: Relations to Viremia and Disease Severity , 2003, Journal of Virology.
[9] T. Burnouf,et al. Nanofiltration of plasma‐derived biopharmaceutical products , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] C. Kempf,et al. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration , 2002, Transfusion.
[11] J. Löwer,et al. Inactivation of parvovirus B19 during pasteurization of human serum albumin , 2002, Transfusion.
[12] A. Groener,et al. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. , 2002, Thrombosis research.
[13] G. Antonelli,et al. Dynamics of Persistent TT Virus Infection, as Determined in Patients Treated with Alpha Interferon for Concomitant Hepatitis C Virus Infection , 2001, Journal of Virology.
[14] D. Josić,et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. , 2000, Thrombosis research.
[15] A. Losikoff,et al. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. , 1998, Biologicals : journal of the International Association of Biological Standardization.
[16] D. Josić,et al. Improved virus safety and purity of a chromatographically produced factor IX concentrate by nanofiltration. , 1995, Journal of chromatography. B, Biomedical applications.
[17] C. Michalski,et al. Large‐Scale Production and Properties of a Solvent‐Detergent‐Treated Factor IX Concentrate from Human Plasma , 1988, Vox sanguinis.
[18] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[19] H. Okamoto. History of discoveries and pathogenicity of TT viruses. , 2009, Current topics in microbiology and immunology.
[20] M. Bendinelli,et al. Immunobiology of the Torque teno viruses and other anelloviruses. , 2009, Current topics in microbiology and immunology.
[22] Tau Fluvalinate,et al. The European Agency for the Evaluation of Medicinal Products , 1997 .